Niraparib Monotherapy in Late-Line Ovarian Cancer

Management of Niraparib Dosing in Ovarian CancerПодробнее

Case 3: Second-Line Therapy for Recurrent Ovarian CancerПодробнее

Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancerПодробнее

Personalized Dosing of Niraparib in Ovarian CancerПодробнее

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Case 1: Use of Niraparib in Ovarian CancerПодробнее

Dr. Penson on Olaparib Monotherapy Vs Chemo for Ovarian CancerПодробнее

Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian CancerПодробнее

Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее

The AVANOVA study: niraparib and bevacizumab for ovarian cancerПодробнее

Comment: Niraparib for ovarian cancerПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Clinical Use of Niraparib in Ovarian CancerПодробнее

Niraparib Maintenance Therapy for Ovarian CancerПодробнее

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian CancerПодробнее

Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian CancerПодробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Ovarian Cancer: Optimizing Treatment With NiraparibПодробнее